Gene therapy for Friedreich’s ataxia
Nature Medicine
April 7, 2014
A gene therapy method corrects the heart defects in a mouse model of Friedreich’s ataxia-which damages both the heart and the nervous system and leads to movement problems. These findings, published this week in Nature Medicine, have potential application for the therapy of individuals with Friedreich’s ataxia.
Individuals with Friedreich’s ataxia harbor mutations in the gene encoding frataxin, an essential mitochondrial protein, and have a variety of symptoms, including neurodegeneration, cardiomyopathy and diabetes. The major cause of mortality in these individuals is heart failure.
Using mice lacking frataxin in the heart, Helene Puccio and her colleagues demonstrate that frataxin gene therapy can correct mitochondrial metabolism and reverse heart damage, raising the possibility of a gene therapy treatment for this disease.
doi: 10.1038/nm.3510
Research highlights
-
May 12
Geoscience: Monitoring earthquakes at the speed of lightNature
-
May 4
Microbiology: Bacteriophage therapy helps treat multi-drug resistant infection in an immunocompromised patientNature Communications
-
Apr 27
Planetary science: Building blocks of DNA detected in meteoritesNature Communications
-
Apr 8
Health: Psilocybin use associated with lower risk of opioid addictionScientific Reports
-
Apr 5
Energy: Winterizing the Texan energy infrastructure pays off in the long termNature Energy
-
Mar 17
Neuroscience: Sample size matters in studies linking brain scans to behaviourNature